Recent investigations of renal cell carcinoma (RCC) have revealed several epigenetic modifications, as well as alterations in the genes and enzymes that regulate these changes. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play a critical role in RCC tumorigenesis. Specific changes in DNA methylation and mutations of histone modifiers have been identified and may be associated with an aggressive phenotype. In addition, the potential of reversing the effects of these enzymes and hence reversing the cellular epigenetic landscape to a ''normal phenotype'' have led to an increasing interest in developing targeted chromatin remodeling agents. However, the translation of the understanding of these changes to the clinic for the treatment of RCC has posed significant challenges, partly due to tumor heterogeneity. This review describes the aberrant histone and DNA alterations recently reported in RCC and highlights the potential targeted chromatin remodeling therapies in the management of this disease. FIGURE 2. Examples of HDAC inhibitor activity and clinical studies in RCC. Summary of the different studies conducted in vitro and in vivo and clinical trials combining HDACs with other agents. Upper panel: genes and pathways affected by HDAC inhibitors. Lower panels: combination clinical trials with HDAC inhibitors.
EPIGENETIC MODIFICATIONS IN CANCER
DNA methylation, covalent histone alterations, noncovalent histone alterations, and noncoding RNAs (not discussed in this review) are the 4 primary types of epigenetic modifications. 1 DNA methylation leads to transcriptional silencing, whereas histone modifications can lead to either transcriptional activation or repression; moreover, these changes can occur along with genetic aberrations that are found in cancer. 1 The potential of reversing these epigenetic variations has led to considerable interest in developing agents that target epigenetic variations. 1 In several tumors, global hypomethylation has been found to be a common occurrence with hypermethylation of CpG islands in the promoter region of certain genes. 2Y4 Hypomethylation can occur in varying degrees in localized versus invasive disease and is thought to lead to tumorigenesis by loss of imprinting, chromosomal instability, and activation of oncogenes. 3 Hypermethylation of CpG islands has been shown to result in silencing of tumor suppressors. 3 Histone modifications, on the other hand, are considered to be more dynamic changes, with different alterations occurring depending on the cell context. 2 Histones are often acetylated (which neutralizes the lysine charge and leads to a more open chromatin and thus transcriptional activation), methylated (activator or repressor), or phosphorylated (altering the structure and function of chromatin). 2 Modifications of the chromatin structure can lead to breaks in the chromosome, which can result in tumorigenesis. 5 Histone alterations, for example, at H3K27me3 (repressive) and H3K4me3 (active), have been shown to be important in the development process, and genes with these alterations have been reported to be targeted for DNA methylation in tumorigenesis. 2 Studies have shown a loss of H4K16Ac and H4K20me3 in different malignancies. Interestingly, misinterpretation of the histone code can also lead to dysregulation of genes involved in normal cell functioning. 5 A review by You and Jones 4 provides an extensive list of epigenetic changes occurring in cancer and agents that can target these changes. This chapter discusses epigenetic modifications occurring in renal cell carcinomas (RCCs) and therapy targeted at these changes. The majority of enzymes involved in DNA methylation and histone modifications, their targets, and inhibitors that target these enzymes are shown in Table 1 and in Figure 1 .
Histone Deacetylases and Histone Deacetylase Inhibitors
Histone deacetylases (HDACs) are subdivided into different classes: class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) that are related to the transcriptional regulator Rpd3 in yeast; class II HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10) related to Hda1 in yeast, and class III HDACs sirtuins (Sirt1YSirt7), which will not be discussed in detail in this chapter. 6Y8 Class I HDACs are primarily located in the nucleus and depend on zinc for their activity; class II HDACs are able to translocate between the nucleus and the cytoplasm and also depend on zinc for their activity, whereas sirtuins are located in the nucleus, cytoplasm, or the mitochondria and depend on NAD + for their activity. 6Y8 Histone deacetylase inhibitors primarily target the zinc domains to exert the biological effects through cell cycle arrest, differentiation, and apoptosis in a variety of tumor models. 6 Histone deacetylase inhibitors are categorized based on their structure into hydroxamates (eg, vorinostat), cyclic peptides (eg, romidepsin), aliphatic acids (eg, phenylbutyrate), and benzamides (entinostat). 8Y10 These small molecules are active at wide range of concentrations in vitro, ranging from millimolar, to micromolar and nanomolar values for butyrates, vorinostat/entinostat, and trichostatin A (TSA)/tetrapeptides, respectively. 8
HDACs and Normal Kidney Cells
The use of HDAC inhibitors or sirtuin activation in some studies has been shown to have protective effects on renal tubular cells upon cisplatin treatment 11, 12 and prevention of transforming growth factor A1Yinduced epithelial-mesenchymal transition (EMT). 13 Treatment with vorinostat during cisplatin treatment reduced apoptosis in renal proximal tubular cells through p53 suppression. In addition, SIRT1 activation during cisplatin treatment in vitro has been shown to prevent HK2 cell apoptosis through deacetylation of the p65 unit of nuclear factor JB. 12 Moreover, TSA treatment of primary renal proximal tubule epithelial cells (RPTEC) cells were found to prevent transforming growth factor A1Yinduced EMT. 13 Using human embryonic kidney (HEK293) cells, researchers have reported that induction of hypoxia leads to down-regulation of RECK (gene involved in suppression of metastasis and angiogenesis 14 ) both at the mRNA and protein levels. Histone deacetylase 1 and hypoxia-inducible factor 1> (HIF-1>) bind to the promoter region of RECK, thus promoting cell migration and invasion. 15 
Histone Modifications in RCC
Seligson et al 16 analyzed 192 localized renal tumors and 163 metastatic RCCs for histone modifications by immunohistochemistry. They found that patients with staining for H3K4me2 and H3K18Ac (associated with active transcription), as well as H3K9me2 (associated with gene repression), correlated with poor prognosis and lower survival probability; these histone modifications were able to predict outcomes independent of the p53 and Ki67 status of the tumors. 16 However, only H3K9me2 was found to be a prognostic indicator of poorer outcome in metastatic patients. 16 Similarly, Mosashvilli et al 17 showed that in 193 RCC patient tumors (inclusive of different histological subtypes) reduction in total H3Ac and H4Ac was associated with worse clinical and pathological characteristics, including metastasis. Specifically, reduction in overall H3K18Ac strongly correlated with recurrence in those patients with localized RCC in this study. 17 A large-scale study that included 142 clear cell RCC (ccRCC) samples, H3K4 methylation levels were inversely correlated with advanced stage, grade, and metastatic parameter of the disease. 18 Lower H3K4 methylation levels also related to shorter progression-free survival with H3K4me2 significantly associated with cancer-specific survival. 18 In another study by the same group using the same patient cohort, similar results were observed with H3K27 methylation status. 19 They showed lower H3K27 methylation levels were associated with worse clinical characteristics, including cancer-specific and progression-free survival. 19 In addition to changes in histone modifications, several changes occurring directly within the histone modifiers have been reported. Histone demethylases UTX, JMJD2, and EZH2 have been found to be up-regulated at the protein and mRNA levels, with a corresponding decrease in H3K27me3. 20 Similarly, the histone acetyltransferase MYST1 has been found to be downregulated in a small set of RCC samples with a corresponding decrease in H4K16Ac (its downstream histone target). 21 In vitro models utilizing the RCC cell lines 786-O and C2 confirmed lower acetylation levels at H4K16 with a decrease in MYST1 when compared with the normal human embryonic kidney cell lines (HEK293). 21 In vitro analysis has also revealed mutations in the histone methyltransferase SETD2 with a corresponding decrease in H3K36me3, but not in H3K36me2. 22 In a smaller set of ccRCC samples, truncating mutations of PBRM1 were found in 5 of 10 tumors, which led to a loss of function in PBRM1 (located at the 3p21 region). 23 BAP1 mutations involved in ubiquitination of histone H2A were also found in the same set of samples, 23 suggesting a role for BAP1 as a putative tumor suppressor gene. 24 Loss of PBRM1 expression 25 was observed in a greater percentage of higher-stage tumors; PBRM1 also served as a prognostic marker with PBRM1-positive patients having better overall survival as compared with those patients with negative staining. 26 Knockdown analysis of PBRM1 in vitro increased cell proliferation, colony formation, and cell migration, leading to speculate that PBRM1 may also function as a tumor suppressor gene. 25 In a large-scale study by Dalgliesh et al, 27 more than 400 tumors were analyzed, and results showed mutations in chromatin remodeling genes including SETD2, JARID1C, UTX, and MLL2, in 3% to 5% of tumors with some correlation with von HippelYLindau (VHL) mutations and tumors with a high hypoxic signature. Renal tumors have been shown to have a higher percentage of global methylation and reduced histone acetylation as compared with nontumor counterparts. 28 Interestingly, in a cluster study by Avissar-Whiting et al, 29 EZH2 was overexpressed in tumors that were less aggressive, and these patients had better prognosis. In addition, class I HDAC, HDAC1 and FIGURE 1. Summary of histone modifications and enzymes involved. The nucleosome structure consists of the octamer core (H2A, H2B, H3, and H4) with the linker histone (H1). Histone tails can be modified through phosphorylation, acetylation, ubiquitination, and methylation. DNA, however, can only be acetylated or methylated at different sites, including promoter regions and CpG islands. Enzymes causing previously mentioned modifications are HDACs, histone acetyltransferases (HATs), histone methyltransferases (HMTs), and histone demethylases (HDMTs). DNA can be methylated by a group of enzymes known as DNA methyltransferases and deacetylated by class II HDACs . HDAC2, have been shown to be overexpressed in ccRCCs, but no correlation with clinical parameters was observed. 30 
HDAC Inhibitors and RCC

HDAC Inhibitors and Protein Ubiquitination
In vitro analyses of 5 renal tumor cell lines treated with either vorinostat or ritonavir alone and in combination showed consistent dephosphorylation of Rb along with a reduction in HDAC1 expression (with no change in HDAC6 expression) and an increase in sub-G1 fraction in combination treatment. 31 The combination also inhibited proliferation and colony formation in renal tumor cells, while having minimal effect on normal renal proximal tubular cells. 31 The same group also showed that the combination of ritonavir and bortezomib induced the acetylation of histone H3 with a similar increase in the sub-G1 fraction. 32 However, the combinations in this model also led to a reduction in HDAC6 expression, unlike the previous study, thereby with increasing protein ubquitination. 32 This group further combined vorinostat and bortezomib and observed similar inhibitory effects on cell proliferation, induction of ubiquitination and apoptosis, and tumor growth inhibition. 33 These studies suggest a potential therapeutic effect in combining HDAC and proteasome inhibitors in RCC.
HDAC and Mammalian Target of Rapamycin Inhibition
Chronic single-agent in vitro treatment of human ccRCC Caki-1 cells with either the mammalian target of rapamycin (mTOR) inhibitor everolimus or the HDAC inhibitor valproic acid (VPA) led to drug resistance, but not with drug combination. 34 This loss of sensitivity to single agents was associated with an increase in EMT markers, whereas combination treatment resulted in stabilization of the EMT markers. 34 In a study using in vitro and in vivo models of 786-0 and Caki-1, established tumors showed greater reduction in cell proliferation and tumor growth using a combination of temsirolimus and vorinostat. 35 In addition, xenografts showed greater reduction in angiogenesis, an increase in apoptosis, and a down-regulation of survivin. 35 Chronic application of VPA has been shown to induce resistance through an increase in HDAC and a decrease in histone acetylation. 36 Hypoxia-inducible factors (HIF) 1> and 2> are critical transcriptional factors in ccRCC, as discussed in other chapters. Histone deacetylase inhibitors have been reported to inhibit HIFs by affecting its stability. 37 Qian et al 37 have shown that HDAC4 and HDAC6 were present in the same complex as HIF-1>, and knockdown of both HDAC4 and HDAC6 lowered HIF-1> expression and activity. 37 A rational combination strategy is to inhibit HIF stability with HDAC inhibitors and HIF protein synthesis by mTOR inhibitors. Using C2 cells and xenografts, the combination treatment showed greater inhibitory effects as well as increased antiangiogenic effects and down-regulation of p-Akt. 38 In an ongoing phase I/II clinical trial (NCT01582009), the combination of panobinostat and everolimus is being evaluated in patients with metastatic RCC who have progressed following antiYvascular endothelial growth factor (VEGF) therapies. A similar phase I study (NCT00169532) is assessing the combination of vorinostat and ridaforolimus in advanced RCC. Figure 2 summarizes the studies with HDAC inhibitors in combination with other agents.
Histone Marks, HDAC Inhibitors, and the VHL-HIF Axis in RCC
Sirt1 has been shown to activate HIF-2> leading to activation of its downstream target Epo, a prosurvival factor that protects stem and progenitor cells. 39 In addition to Sirt1, other histonemodifying genes such as the JMJC family of histone demethylases have been shown to be targets of the HIF pathway. 40 These enzymes were activated under low oxygen concentrations, however global changes in their downstream histone target H3K9 was not observed. 40 Similar results showed that HIF1> specifically regulates JMJD1A and JARID1B. 41, 42 The authors analyzed specific targets of hypoxia, including ADM, EDN1, and others to show that although global H3K9 changes were not observed upon hypoxic induction, the promoters at these specific genes showed a decrease in H3K9 methylation. 42 In vitro analyses have also revealed that RCC4 and RCC10 (VHL null) cell lines have higher H3K27me3 and K3K9me3 status and lower H3K4me3 status as compared with VHL wild-type counterparts. 43 In another study, 786-O cell lineYderived metastatic tumors had higher H3K4me3 levels and lower H3K27me3 levels in genes that were upregulated in the metastatic sites. 44 In particular, introduction of VHL in the metastatic cell lines reduced the activation mark H3K4me3 at the CXCR4 loci, 44 a chemokine receptor involved in migration and metastasis. 45 In 5 of 10 ccRCC clinical tumors, Fragile Histidine Triad (FHIT) was found to be hypermethylated in ccRCC; however, because of the limited number of samples, the authors were not able to establish a correlation of FHIT methylation to any clinical parameters. 46 Based on the preclinical evidence that HDAC inhibitors induce HIF degradation, the combination of HDAC and VEGF inhibition has recently been tested. A clinical trial evaluated the combination of vorinostat (200 mg twice daily for 2 weeks) and the VEGF blocker bevacizumab (15 mg/kg intravenously over 3 weeks) in patients with previously treated RCC. This combination was well tolerated, and promising clinical benefit was observed. In 34 patients previously treated with a wide range of targeted therapies, 6 objective responses were observed, and 19 patients had prolonged stable disease. 47 Future studies will evaluate the angiogenic and epigenetic signatures that may be associated with resistance to anti-VEGF therapies and more suitable for treatments with HDAC inhibitors.
HDAC Inhibitors and Tyrosine Kinase Inhibitors
In vitro studies using renal tumor cell lines with different VHL status showed synergistic effects and an increase in caspasedependent apoptosis when cells were pretreated with the HDAC inhibitor belinostat followed by sorafenib. 48 The HDAC inhibitor VPA also acted in concert with another tyrosine kinase inhibitor, AEE788, to inhibit cell proliferation by Akt inhibition. 49 Combination of HDAC and VEGF receptor tyrosine kinase inhibition has been shown to be effective in inhibiting the HIF-VEGF axis, suggesting a rational combination strategy to be tested in clinical trials. 50 
HDAC Inhibitors and Differentiation Agents
Histone deacetylase inhibitors have also been combined with differentiation agents. The retinoic acid receptor RAR-A2 is commonly methylated in epithelial tumors including RCC, and retinoid resistance has been a major hurdle in differentiation therapy. Renal cell carcinoma cell lines re-express RAR-A2 following treatment with all-trans retinoic acid and TSA, with the combination having enhanced effects on inhibition of cell proliferation and tumor growth, in vitro and in vivo, respectively. 51 In another study, vorinostat and 13-cis retinoic acid (CRA) treatment of a different set of renal cell lines showed similar results with greater growth inhibition of cells in vitro and an induction of a different set of genes in the combination-treated cells, including RAR-A2. 52 Re-expression of RAR-A2 in renal cells inhibited cell proliferation in vitro and tumor growth inhibition in vivo. 53 Entinostat treatment in vivo restored CRA sensitivity, in part through re-expression of RAR-A2, thus resulting in greater tumor growth inhibition with combination treatment. 53 In a phase I clinical trial (NCT00098891), 19 patients were treated with the combination of entinostat (4 mg/m 2 weekly) and CRA (1 mg/kg daily). The treatment was well tolerated, and although objective responses were not observed, some patients, including one with RCC, benefited from prolonged stables disease after failure of prior therapies. 54 A phase I/II trial (NCT-00324740) has tested the combination of vorinostat and CRA in patients with advanced RCC with evidence of clinical benefit in patients for refractory RCC. 55 These evidences support further testing of differentiation agents and HDAC inhibitors in RCC.
HDAC Inhibitors and Immunomodulation
Preclinical and clinical experience with HDAC inhibitors has suggested a possible immunomodulatory activity of these agents. The combination treatment of entinostat and high-dose interleukin 2 (IL-2) has shown a greater inhibitory effect in the murine renal cell carcinoma model as compared with treatment with single agents with an observed decrease in regulatory T cells (Tregs) and increased cytotoxicity in the combination-treated xenografts. 56 The combination also increased survival and reduced metastasis formation in this model. 56 Furthermore, Shen et al 57 have reported that entinostat inhibited IL-2Yinduced Foxp3 induction and Treg activity. This study suggests that class IYspecific HDAC inhibition has a greater inhibitory effect on Tregs than a pan-HDAC inhibitor through the increased acetylation of STAT3 and thereby its regulation of Foxp3. 57 Another study compared the in vitro and in vivo effects of single agents VPA and interferon F to the combination treatments and found that the combination induced enhanced tumor inhibition with greater acetylation of histone H3 and inhibition of HDAC activity. 58 An ongoing multicenter phase I/II clinical trial (NCT01038778) is studying the safety and tolerability of high-dose IL-2 with class I HDAC inhibitor entinostat in patients with metastatic RCC. Preliminary data suggest acceptable toxicity and early signs of promising clinical benefit as compared with historical data. 59 Future preclinical and clinical studies will further exploit the immunomodulatory activity of HDAC inhibitors and will likely test novel combination strategies, including immune checkpoint inhibitors and vaccines.
HDAC Inhibitors and Apoptosis-Inducing Agents
Apoptosis was induced through induction of tumor necrosis factor (TNF)-related apoptosis-inducing ligand or TRAIL and caspases following treatment of renal cell lines infected with Ad5-TRAIL and treated with class IYspecific HDAC inhibitors. 60 Histone deacetylase inhibitors, including romidepsin, vorinostat, and apcidicin, decreased CXCL12-induced cell migration, with an up-regulation of p21 and acetylated histone H3, classic markers of HDAC inhibitors. 61 In addition, class IYspecific HDAC inhibitors did not induce apoptosis in renal proximal tubular cells, which led the authors to speculate that the HDAC inhibitors are selective for tumor cells and have less of an effect on normal cells. 60 Treatment of different cell lines with differential acetylated H3 status showed different sensitivity to romidepsin, with an induction of p21 either inducing cell cycle arrest or apoptosis. 62 Romidepsin has been evaluated in a clinical trial as a monotherapy in refractory RCC. However, this treatment did not result in objective clinical response. 63 
Methylation in RCC
Several reports have suggested the presence of numerous methylated genes in RCC. 64Y67 In the analysis of 67 RCC specimens, the lowest degree of methylation was associated with lowerstage tumors. 29 sFRP2, an antagonist of the Wnt pathway, has been found to be silenced in tumors as compared with nontumor counterparts, as well as in renal tumor cell lines compared with normal human kidney cells. 68 sFRP2 is involved in anchorage independent growth, invasion, and apoptosis. It was highly methylated at the promoter region, and its expression was induced by treatment by the demethylating agent 5-Aza-dC, but with greater induction by TSA as it increased acetylation of histone H3 and H4 at the promoter regions. 68, 69 However, these effects of TSA and combination varied with different cell lines. 69 DLEC1, a tumor suppressor gene, has been found to be silenced by methylation in gastric and colon cancer, 70 and similar results were found in renal cell lines and tumors. 71 DLEC1 is re-expressed in cell lines when treated with Aza and TSA, and DLEC1 re-expression reduced colony formation in renal cell lines. 71 The combination of vinblastine (a cytotoxic agent) and 5-Aza-dC induced expression of p21 with an accumulation of sub-G1 populations, reduction of antiapoptotic gene Bcl2, and a reduction in tumor growth in xenografts. 72 Microarray analysis of cell lines treated with 5-Aza-Dc and TSA for 24 hours revealed up-regulation of several genes, including genes involved in migration, adhesion, and growthpromoting pathways. 73 The authors also confirmed the methylation of these genes by methylation-specific polymerase chain reaction of both the cell lines analyzed as well as 32 localized renal tumors. 73 In a study with a different set of renal cell lines, upon treatment with 5-Aza-dC, a large set of genes was upregulated, and some of these genes had tumor suppressor activity. 74 In a study of 51 patient ccRCC tumors, tumors were classified into 2 subgroups based on the methylation profiles of their adjacent nontumor tissue, and one of the subgroups had tumors with more nodular, vascular, and renal vein involvement and higher tumor stages and grades and higher tumor recurrence. 75, 76 Overall, these data support the testing of demethylating agents and HDAC inhibitors in RCC. Further preclinical studies will hopefully identify the methylome signature most suitable for this therapeutic approach.
CONCLUSIONS
Alterations in histone status and DNA methylation occur in RCC and are rational targets for therapeutic interventions by using agents against enzymes regulating these changes. However, clinical translation of these agents has been challenging as the use of HDAC inhibitors as single agents has not yielded significant clinical benefit. However, the rational combination of different compounds and the identification of those patients with significant modifications in clinically relevant epigenetic enzymes will likely provide a beneficial effect. In addition, the utilization of histone and methylation changes as potential biomarkers of response to different therapies, including antiangiogenics and immunotherapies, is exciting. A greater understanding of epigenetic alterations will provide new effective therapies for the treatment of RCC.
